Nitroglycerin (or glyceryl trinitrate, GTN) has been long considered an endothelium-independent vasodilator because GTN vasodilation is intact in the absence of the endothelium and in the presence of endothelial dysfunction. However, in animal and in vitro models, GTN has been shown to stimulate the release of certain endothelium-derived vasodilators such as nitric oxide (NO) and prostacyclin (PGI 2 ). In addition, chronic GTN therapy leads to endothelial dysfunction. In this series of experiments, we explored how GTN might interact with the vascular endothelium in normal humans, without cardiovascular disease or risk factors associated with abnormalities in vascular function.
Introduction
Since its therapeutic properties were initially described in 1879 [1] , glyceryl trinitrate (GTN), also known as nitroglycerin, has been used to treat angina, acute coronary syndromes and congestive heart failure [2-4]. Although GTN has long been considered to be an endothelium-independent vasodilator, with potent effects on venous capacitance vessels and conduit arteries [2, 3] , a number of lines of evidence suggest that some of the vascular effects of GTN may, in part, be to effect mediated by the endothelium [4] . Studies performed in animal models suggest that acute administration of GTN stimulates the basal activity of endothelial nitric oxide synthase (eNOS) [5] and inhibition of eNOS can significantly decrease GTN-mediated vasodilation [6] . In addition, studies in cultured human endothelial cells have demonstrated the ability of GTN to stimulate synthesis of prostacyclin (PGI 2 ) [7] , a potent vasodilator derived from the vascular endothelium [8] . However, these observations should be interpreted with caution as these endothelial cells were extracted from conduit arteries, which might not be applicable to other vascular distributions. GTN may also affect endothelium-derived hyperpolarizing factors (EDHFs) since chronic GTN therapy is found to downregulate the EDHF pathway [9] . Epoxyeicosatrienoic acids, which are metabolites of arachidonic acid, have been identified as EDHFs [10] . In vivo studies in animals and humans have also suggested that epoxyeicosatrienoic acids are involved in the regulation of vascular tone [11] [12] [13] [14] [15] [16] [17] [18] . In humans, miconazole, a cytochrome P 450 inhibitor, decreases bradykinin-induced vasodilation in the presence of eNOS and cyclooxygenase (COX) inhibition [15] . Another cytochrome P 450 antagonist, fluconazole, caused a small decrease in basal vascular tone in healthy volunteers [16] [17] [18] . To date, no study has explored whether the acute effects of GTN might be mediated in part by EDHFs.
It is now known that chronic GTN therapy is associated with the development of endothelial dysfunction [19, 20] , which has been demonstrated to occur in both peripheral resistance vessels [21] [22] [23] as well as peripheral and coronary conduit arteries [24] . Mechanistic studies demonstrate that chronic GTN therapy results in an increase in free radical production, which causes a decline in eNOS function [21, 22, 25, 26] and a decrease in the activity of PGI 2 synthase [27] . In addition, chronic GTN therapy has also be shown to cause a downregulation on the EDHF pathway, although the mechanism and consequences of this effect remain unclear [9] . These observations indicate that there is an interaction between GTN and endothelium-derived vasodilatory mediators. In the current study, we examined the role of vascular endothelium in GTN-mediated vasodilation in humans to determine whether, in part, it involves the endothelium-derived vasodilators eNOS, PGI 2 and/or epoxyeicosatrienoic acids.
Methods
The protocols described herein were approved by the Mount Sinai Hospital Research Ethics Board and written informed consent was obtained from all participants.
Experimental protocol
Fifty-eight healthy, non-smoking males aged between 18 and 30 were recruited to participate in the study. Of this total, 48 were divided into three groups of 16 who were randomly assigned to sequential intra-arterial infusions of GTN in the presence and absence of Levo-N-monomethylarginine (L-NMMA), ketorolac or fluconazole, which are inhibitors of the production of endothelium-derived NO, PGI 2 and epoxyeicosatrienoic acids, respectively. The remaining 10 subjects were assigned to receive two sequential infusions of GTN and serve as a control. All subjects received local anesthetic and had a 3 French arterial line inserted into the brachial artery of the non-dominant arm using a Seldinger technique. Each subject first received normal saline infusion for 15 min and baseline forearm blood flow (FBF for baseline 1) was determined during the last 3 min. Immediately after baseline 1 was recorded, subjects received three infusions of GTN at increasing infusion rates of 10, 30 and 100 nmol min À1 . Each infusion lasted for 7 min and FBF measurements were performed continuously during the last 3 min followed by a 4 min washout period before the next infusion was initiated. The last infusion of GTN (100 nmol min À1 ) was followed by a washout interval of 10 min. Depending on the assigned treatment, each subject then received a 15 min infusion of normal saline (control condition), L-NMMA (a loading dose of 5 mg min À1 for 5 min followed by a maintenance dose of 1.25 mg min
À1
and a co-infusion of verapamil at 3.5 μg min À1 for 10 min), ketorolac (a loading dose of 600 μg min À1 for 5 min followed by a maintenance dose of 300 μg min À1 for 10 min), or fluconazole (0.4 μg min À1 for 15 min), immediately after which a new baseline FBF (baseline 2) was measured for 3 min in the presence of normal saline or one of these inhibitors. The infusion rates of L-NMMA, ketorolac and fluconazole were derived from previous clinical studies that demonstrated effective inhibition of NO, PGI 2 and epoxyeicosatrienoic acids, respectively [16, 18, [28] [29] [30] [31] [32] [33] [34] [35] . The infusion rate of verapamil was determined in a pilot study (n = 10) where it was co-infused with L-NMMA to prevent the reduction in FBF which is associated with NOS inhibition [36] [37] [38] [39] . In the pilot study, infusion of L-NMMA was initiated with a loading dose of 5 mg min À1 for 5 min followed by a maintenance dose of 1.25 mg min À1 for 10 min. Co-infusion of verapamil was then initiated starting at a rate 10 μg min À1 , based on prior reports [40, 41] , and continued for 10 min until a steady-state FBF was observed. This procedure was repeated in further volunteers until an infusion rate of verapamil (3.5 μg min À1 ) that, in combination with L-NMMA, resulted in FBF that was similar to the baseline value prior to the infusion of L-NMMA. After L-NMMA (and verapamil), ketorolac and fluconazole had been infused for 15 min, those infusions were continued while intra-arterial GTN was again infused using the same infusion rates (10, 30 and 100 nmol min À1 ). All drugs were prepared in normal saline and all the infusions were kept at a constant rate of 0.8 ml min À1 with a precision pump (Harvard apparatus, South Natick, Massachusetts). The experimental protocol is summarized in Figure 1 . Intra-arterial blood pressure and heart rate were recorded after each infusion (PowerLab 8/30) using the average of 15 cardiac cycles. The electrocardiogram was monitored continuously. FBF was determined on both arms by venous occlusion strain-gauge plethysmography (D.E. Hokanson Inc., Bellevue, Washington) with calibrated mercury-in-silastic strain gauges. Briefly, circulation of the hand was excluded by inflating a wrist cuff to 200 mm Hg during measurement periods. The upper arm cuff was inflated to 54 mm Hg and deflated at 10 s intervals (Hokanson rapid cuff inflator, D.E. Hokanson Inc. , Bellevue, Washington) for a period of 3 min, and FBF was recorded as the average of consecutive measurements. FBF was measured simultaneously in both arms and the responses. All FBF values were presented as the ratio of the infused vs. the non-infused arm. This approach to the measurement of FBF normalizes the results obtained for the normal variability of FBF over time and is considered more repeatable and reliable than the absolute values of FBF in the infused arm alone. This is a standard approach used by our laboratory and others [22, 23, 41, 42] that allows for an assessment of changes in FBF associated with drug infusions while accounting for systemic influences on FBF which are reflected by changes in the non-infused arm.
Statistical analysis
Two-way analysis of variance (ANOVA), with appropriate contrast statements, was performed using SPSS Statistics (version 24) to analyse the changes in FBF in response to GTN at various infusion rates in the presence of one of the three endothelium inhibitors to determine the significance of vascular endothelium in GTN-mediated vasodilation. A statistical significance level of <0.05 was taken as the threshold. For all results, post hoc comparisons between groups were performed with the Bonferroni correction. All results are expressed as mean ± SEM.
Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to corresponding entries in http://www. guidetopharmacology.org, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY [43] , and are permanently archived in the Concise Guide to PHARMACOLOGY 2017/18 [44] .
Results

Effect of repeated infusions of GTN combined with saline
In the absence of any endothelium inhibitor, intra-arterial GTN infusions had no effect on mean arterial blood pressure (MAP) and heart rate (HR) ( Table 1) . GTN caused a significant dose-dependent increase in FBF which was not altered after repeated administration (Figure 2 ).
Pilot study: effect of L-NMMA combined with verapamil on FBF
The pilot study showed that L-NMMA alone significantly decreased FBF (0.85 ± 0.11 vs. 1.22 ± 0.12 at baseline, P < 0.05) and the co-infusion of L-NMMA and verapamil (3.5 μg min À1 ) restored FBF to a level similar to baseline (1.45 ± 0.16 vs.
1.22 ± 0.12 at baseline, P = NS).
Effect of L-NMMA (and verapamil) on GTN responses
Intra-arterial GTN infusions had no effect on MAP; however, there was a small but significant increase in HR after GTN infusions in the presence of L-NMMA and verapamil (Table 1) . FBF at baseline (baseline 1) and in the presence of L-NMMA and verapamil (baseline 2) was similar. GTN caused a significant dose-dependent increase in FBF which was not altered in the presence of L-NMMA and verapamil (Figure 2 ).
Figure 1
Summary of experimental procedures: the procedure timeline for all four experimental conditionsGTN = glyceryl trinitrate (or nitroglycerin).
Effect of ketorolac on GTN responses
Intra-arterial GTN infusions had no effect on MAP or HR in the absence or presence of ketorolac (Table 1 ). FBF at baseline (baseline 1) and in the presence of ketorolac (baseline 2) was similar. GTN caused a significant dose-dependent increase in FBF which was not altered in the presence of ketorolac (Figure 2 ).
Effect of fluconazole on GTN responses
Intra-arterial GTN infusions had no effect on MAP or HR in the absence or presence of fluconazole. FBF at baseline (baseline 1) and in the presence of fluconazole (baseline 2) was similar. GTN caused a significant dose-dependent increase in FBF which was not altered in the presence of fluconazole (Figure 2 ).
Discussion
The current study examined the role of vascular endothelium in in vivo GTN-mediated vasodilation in humans. We used the brachial artery infusion forearm blood flow model in order to avoid systemic haemodynamic effects and consequent reflex neurohormonal responses. Indeed, our results Values expressed as mean ± SEM a P < 0.05 compared to the baseline HR value in the presence of L-NMMA
Figure 2
The effect of endothelium inhibition on GTN-mediated vasodilation: forearm blood flow responses to intra-arterial infusions of GTN in the absence and presence of endothelium inhibitor L-NMMA, ketorolac, and fluconazoleFBF = forearm blood flow; GTN = glyceryl trinitrate (or nitroglycerin)
demonstrate that the systemic effects of intra-arterial GTN infusions on blood pressure and heart rate were largely neutral (Table 1) , suggesting minimal impact from the peripheral nervous system in response to the local vasodilatory effect of GTN. Feelisch et al. demonstrated the production of NO when GTN was incubated with human endothelial cells [45] . In other in vitro endothelial cell models, GTN was shown to increase the update of L-arginine, a precursor of NO [5] , and stimulate eNOS [5, 6] possibly via activation of the phosphatidylinositol 3-kinase and protein kinase B pathways [46] . These prior findings suggest that GTN could stimulate the production of endothelial NO contributing to its vasodilatory effect. Interestingly, a clinical study found that intra-arterial administration of GTN at doses that did not change resting blood flow increased FBF responses to subsequent intra-arterial infusions of acetylcholine, a known endothelium-dependent vasodilator, in patients with congestive heart failure (CHF) but not healthy volunteers [47] , indicating that there was no interaction between GTN and acetylcholine in healthy volunteers thereby suggesting there was no interaction between GTN and the endothelium in this population. We compared the vasodilatory effect of GTN in the resistance vascular bed in the forearm in the presence and absence of L-NMMA and found that the effect was not altered by the pharmacological inhibition of endothelial NO production (Figure 2) . Consistent with previous observations [47] , our findings suggest that either endothelial NO is not crucial to GTN-mediated dilation of resistance vessels or inhibition of endothelial NO production alone is not sufficient to alter the vasodilatory effect of GTN in healthy volunteers. However, our observation might not be applicable to predicting the role of endothelium in the GTN-mediated dilation of other vessel types. Similar to our observations, the vasodilatory effect of sodium nitroprusside, a spontaneous NO donor, on resistance vessels is not altered by NO synthase inhibition [16, 48] . However, NO inhibition has been shown to enhance the in vivo vasodilatory effect of this NO donor in human conduit arteries [17] and veins [49] . Therefore, it is possible that eNOS might play a different role in the effect of GTN in other types of blood vessels. It is also possible that other commonly used organic nitrates including isosorbide dinitrate and isosorbide-5-mononitrate might have different interactions with eNOS depending on the specific vascular bed.
The evidence of a possible interaction between GTN and vasoactive prostaglandins has been inconsistent. GTN, at clinically relevant concentrations, has been shown to increase the production of prostacyclin (PGI 2 ) in cultured human endothelial cells [7] as well as saphenous [50, 51] and umbilical [50] veins. The mechanism via which GTN might increase PGI 2 production in these studies was unclear. Since sodium nitroprusside, a spontaneous NO donor, did not have an effect on PGI 2 production [51] , it is possible that GTN itself (without biotransformation into NO or NO-like moiety) might be able to stimulate one of the enzymes in the PGI 2 synthesis pathway. Since indomethacin, a non-selective cyclooxygenase inhibitor, and a specific thromboxane A 2 synthase inhibitor were shown to decrease and enhance GTN-stimulated release of PGI 2 , respectively [50, 51] , it seems likely that GTN might stimulate PGI 2 synthase and increase its activity. In contrast, another study found that GTN, at therapeutic concentrations, does not alter basal level of PGI 2 in human saphenous veins and mesenteric arteries [52] . Clinical observations concerning the role of endothelium-derived PGI 2 on the pharmacodynamic effects of GTN failed to find an important interaction. Studies using aspirin, which inhibits the production of PGI 2 , potentiated the early hypotensive effect of sublingual GTN although this enhancement appeared to be mediated by changes in GTN pharmacokinetics [53] [54] [55] . We elected to examine whether PGI 2 is involved in mediating the vasodilatory effect of GTN using a forearm infusion model. Our results show that the vasodilatory effect of GTN on resistance vessels in the forearm was not changed by pharmacologic inhibition of PGI 2 production with ketorolac ( Figure 2 ). Our findings do not support the hypothesis that a component of vascular responses to GTN is mediated by PGI 2 in the human peripheral resistance vascular bed. Alternatively, it is possible that the concurrent inhibition of endothelium-derived vasoconstrictor thromboxane A 2 production by ketorolac, an inhibitor of cyclooxygenase which synthesizes the common precursor of both PGI 2 and thromboxane A 2 , might have counteracted the potential change resulting from the inhibition of PGI 2 production. This is unlikely since GTN has been shown to have no effect on endothelial thromboxane A 2 production [50] .
Epoxyeicosatrienoic acids (EETs) have been identified as EDHFs that might act as a compensatory mechanism to regulate blood flow when NO and PGI 2 production is inhibited in human vessels [56] , a role that might be particularly important in resistance vessels [57] . To date, there have been no studies examining the potential role of EDHFs as mediators of the vasodilator responses to GTN. In light of this, we hypothesized that GTN would stimulate the release of EETs or have a synergistic interaction with these EDHFs, enhancing the overall vasodilatory effect of GTN. We examined whether inhibition of the production of EETs with fluconazole, an inhibitor of EETs producing enzymes (cytochorome P 450 2C and 2J), would inhibit GTN-mediated dilation of resistance vessels. We found that fluconazole did not cause any change in the vasodilatory effect of GTN. This suggests that EETs do not play a significant role in GTN-mediated dilation of peripheral resistance vasculature.
Conclusion
Our current observations suggest GTN-mediated dilation of forearm resistance vessels is largely independent of vascular endothelium. Over the past decade, GTN and acetylcholine have been used as endothelium-independent and -dependent vasodilators of forearm resistance vessels, respectively, in human studies examining endothelium dysfunction [22, 23, 42, 58] . The current study provides further evidence which supports the use of GTN as an endothelium-independent vasodilator of resistance vessels.
Study limitations
Although not examined in the current study, it is possible that GTN could stimulate the production of multiple Vascular endothelium and nitroglycerin-mediated vasodilation endothelial vasodilator species which may have compensatory capacity. In this case, inhibition of only individual vasodilator species might not be sufficient to cause a significant overall change in the vasodilatory effect of GTN. Although this possibility is acknowledged, the current findings suggest that GTN-mediated dilation of the resistance vessels is largely independent of the vascular endothelium. However, it needs to be emphasized that our findings are restricted to the interaction between endothelium-dependent vasodilators and the response of arterial resistance vessels to GTN. We have only explored the effect of the endothelium on GTN-mediated dilation of forearm resistance vessels. We are unable to comment on whether our observations could be applied to other blood vessel types such as venous capacitance vessels and conduit arteries. It is possible that the endothelium may play a more important role as a mediator of GTN effects in veins and/or the conductance arterial system. In addition, we would like to acknowledge that the experimental conditions of previous in vitro studies are not directly comparable to the in vivo nature of our study. It is possible that the experimental conditions of prior in vitro studies and, in some cases, species differences explain how our results differ from those prior reports.
